Metcalfe Anthony D, Ferguson Mark W J
UK Centre for Tissue Engineering, Faculty of Life Sciences, University of Manchester, 3.239 Stopford Building, Oxford Road, Manchester, UK
J R Soc Interface. 2007 Jun 22;4(14):413-37. doi: 10.1098/rsif.2006.0179.
Advanced therapies combating acute and chronic skin wounds are likely to be brought about using our knowledge of regenerative medicine coupled with appropriately tissue-engineered skin substitutes. At the present time, there are no models of an artificial skin that completely replicate normal uninjured skin. Natural biopolymers such as collagen and fibronectin have been investigated as potential sources of biomaterial to which cells can attach. The first generation of degradable polymers used in tissue engineering were adapted from other surgical uses and have drawbacks in terms of mechanical and degradation properties. This has led to the development of synthetic degradable gels primarily as a way to deliver cells and/or molecules in situ, the so-called smart matrix technology. Tissue or organ repair is usually accompanied by fibrotic reactions that result in the production of a scar. Certain mammalian tissues, however, have a capacity for complete regeneration without scarring; good examples include embryonic or foetal skin and the ear of the MRL/MpJ mouse. Investigations of these model systems reveal that in order to achieve such complete regeneration, the inflammatory response is altered such that the extent of fibrosis and scarring is diminished. From studies on the limited examples of mammalian regeneration, it may also be possible to exploit such models to further clarify the regenerative process. The challenge is to identify the factors and cytokines expressed during regeneration and incorporate them to create a smart matrix for use in a skin equivalent. Recent advances in the use of DNA microarray and proteomic technology are likely to aid the identification of such molecules. This, coupled with recent advances in non-viral gene delivery and stem cell technologies, may also contribute to novel approaches that would generate a skin replacement whose materials technology was based not only upon intelligent design, but also upon the molecules involved in the process of regeneration.
利用我们对再生医学的了解以及适当的组织工程皮肤替代品,有望实现治疗急慢性皮肤伤口的先进疗法。目前,尚无完全复制正常未受伤皮肤的人造皮肤模型。胶原蛋白和纤连蛋白等天然生物聚合物已被研究作为细胞可以附着的潜在生物材料来源。组织工程中使用的第一代可降解聚合物是从其他外科用途改编而来的,在机械性能和降解性能方面存在缺点。这导致了合成可降解凝胶的发展,主要作为一种原位递送细胞和/或分子的方法,即所谓的智能基质技术。组织或器官修复通常伴随着纤维化反应,从而导致疤痕的形成。然而,某些哺乳动物组织具有完全再生而不形成疤痕的能力;很好的例子包括胚胎或胎儿皮肤以及MRL/MpJ小鼠的耳朵。对这些模型系统的研究表明,为了实现这种完全再生,炎症反应会发生改变,从而减少纤维化和疤痕形成的程度。从对哺乳动物再生的有限例子的研究中,也有可能利用这些模型进一步阐明再生过程。挑战在于识别再生过程中表达的因子和细胞因子,并将它们整合起来,以创建一种用于皮肤等效物的智能基质。DNA微阵列和蛋白质组学技术使用方面的最新进展可能有助于识别此类分子。这与非病毒基因递送和干细胞技术的最新进展相结合,也可能有助于采用新方法来生成一种皮肤替代品,其材料技术不仅基于智能设计,还基于再生过程中涉及的分子。